Treatment of autoimmune diseases through manipulation of antigen presentation.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Critical Reviews in Immunology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 9419440
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The molecular basis for HLA class II associations with rheumatoid arthritis

  2004cited by this paper
• Accessory molecule and costimulation requirements for CD4 T cell response.

  1997cited by this paper
• Vaccination with peptides from MHC class II beta chain hypervariable region causes allele-specific suppression of EAE.

  1996cited by this paper
• Models of T cell anergy: is there a common molecular mechanism?

  1996cited by this paper
• Induction of tolerance in experimental autoimmune myasthenia gravis with solubilized MHC class II:acetylcholine receptor peptide complexes.

  1995cited by this paper
• A synthetic peptide from the third hypervariable region of major histocompatibility complex class II beta chain as a vaccine for treatment of experimental autoimmune encephalomyelitis.

  1994cited by this paper
• Specific tolerance to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4+ lymphocytes by soluble major histocompatibility complex class II-peptide complexes.

  1994cited by this paper
• Maternal‐fetal disparity in HLA class II alloantigens and the pregnancy‐induced amelioration of rheumatoid arthritis

  1993cited by this paper
• Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation.

  1993cited by this paper
• Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein.

  1993cited by this paper
• Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1

  1993cited by this paper
• Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients.

  1993cited by this paper
• Contribution of inherited factors to rheumatoid arthritis.

  1992cited by this paper
• Stimulation or tolerization of an anti-myelin basic protein T lymphocyte line with membrane fragments from antigen presenting cells.

  1992cited by this paper
• HLA haplotype sharing in rheumatoid arthritis sibships: risk estimates in siblings.

  1992cited by this paper
• The HLA association with rheumatoid arthritis.

  1992cited by this paper
• Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes.

  1991cited by this paper
• HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation.

  1991cited by this paper
• T-cell recognition of an immuno-dominant myelin basic protein epitope in multiple sclerosis

  1990cited by this paper
• Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals.

  1990cited by this paper
• Myelin basic protein‐specific T lymphocyte lines from MS patients and healthy individuals

  1990cited by this paper
• Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors.

  1990cited by this paper
• Inhibition of experimental autoimmune thyroiditis in mice by anti-I-A antibodies.

  1987cited by this paper
• Stimulation of normal inducer T cell clones with antigen presented by purified Ia molecules in planar lipid membranes: specific induction of a long-lived state of proliferative nonresponsiveness.

  1987cited by this paper
• Antigen presentation by chemically modified splenocytes induces antigen- specific T cell unresponsiveness in vitro and in vivo

  1987cited by this paper
• The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis.

  1987cited by this paper
• Inhibition of IL 2-driven proliferation of murine T lymphocyte clones by supraoptimal levels of immobilized anti-T cell receptor monoclonal antibody.

  1987cited by this paper
• Sequence analysis and structure-function correlations of murine q, k, u, s, and f haplotype I-A beta cDNA clones.

  1986cited by this paper
• Type II collagen-induced arthritis in mice. III. Suppression of arthritis by using monoclonal and polyclonal anti-Ia antisera.

  1985cited by this paper
• Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies

  1983cited by this paper
• In vivo therapy with monoclonal anti-I-A antibody suppresses immune responses to acetylcholine receptor.

  1983cited by this paper
• Antibodies in the sera of patients with systemic lupus erythematosus that block the binding of monoclonal anti-Ia to Ia-positive targets also inhibit the autologous mixed lymphocyte response.

  1982cited by this paper
• In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis.

  1981cited by this paper
• Altered reactivity in mixed lymphocyte culture of lymphocytes from patients with rheumatoid arthritis.

  1969cited by this paper

• Cytokine Imbalance as a Common Mechanism in Both Psoriasis and Rheumatoid Arthritis

  2017cites this paper
• Targeting the B7 Family of Co-Stimulatory Molecules

  2012cites this paper
• Peptide-based therapies for arthritis

  2007cites this paper
• Advances in the treatment of autoimmune diseases; cellular activity, type-1/type-2 cytokine secretion patterns and their modulation by therapeutic peptides.

  2005cites this paper
• Cell-Based Immunotherapy with Suppressor CD8+ T Cells in Rheumatoid Arthritis1

  2005cites this paper
• Acute Disseminated Encephalomyelitis in Childhood: Epidemiologic, Clinical and Laboratory Features

  2004cites this paper
• Antibodies Using Complex-Specific Monoclonal Synovia of Rheumatoid Arthritis Patients Cartilage Glycoprotein-39 Complexes in Localization of MHC Class II / Human

  2003cites this paper
• Localization of MHC Class II/Human Cartilage Glycoprotein-39 Complexes in Synovia of Rheumatoid Arthritis Patients Using Complex-Specific Monoclonal Antibodies

  2003cites this paper
• The Role of Adjuvants in the Efficacy of a Peptide Vaccine for Myasthenia Gravis

  2001cites this paper
• The autoimmune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and new immunotherapies.

  2001cites this paper
• β-Amino Acid Scan of a Class I Major Histocompatibility Complex-restricted Alloreactive T-cell Epitope*

  2001cites this paper
• MHC-based diagnostics and therapeutics - clinical applications for disease-linked genes.

  1999cites this paper
• Rationale and risks of novel immunomodulatory therapies in rheumatoid arthritis.

  1999cites this paper